Literature DB >> 29596911

Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.

Roberta Minari1, Paola Bordi1, Silvia La Monica2, Anna Squadrilli1, Alessandro Leonetti1, Lorena Bottarelli3, Cinzia Azzoni3, Costanza Anna Maria Lagrasta3, Letizia Gnetti3, Nicoletta Campanini3, Pier Giorgio Petronini2, Roberta Alfieri4, Marcello Tiseo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29596911     DOI： 10.1016/j.jtho.2018.03.013

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  12 in total

Review 1.  Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?

Authors:  Elisa Bertoli; Elisa De Carlo; Alessandro Del Conte; Brigida Stanzione; Alberto Revelant; Kelly Fassetta; Michele Spina; Alessandra Bearz
Journal:  Int J Mol Sci       Date:  2022-06-22       Impact factor: 6.208

Review 2.  Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer.

Authors:  Jialiang Yang; Yan Hui; Yanxiang Zhang; Minghui Zhang; Binbin Ji; Geng Tian; Yangqiang Guo; Min Tang; Lianxing Li; Bella Guo; Tonghui Ma
Journal:  Front Oncol       Date:  2021-08-05       Impact factor: 6.244

3.  Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients.

Authors:  Anna Buder; Ellen Heitzer; Julie Waldispühl-Geigl; Sabrina Weber; Tina Moser; Maximilian J Hochmair; Klaus Hackner; Peter Errhalt; Ulrike Setinek; Martin Filipits
Journal:  Biomolecules       Date:  2021-04-21

Review 4.  Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance.

Authors:  Emna Mahfoudhi; Charles Ricordel; Gwendoline Lecuyer; Cécile Mouric; Hervé Lena; Rémy Pedeux
Journal:  Front Oncol       Date:  2022-04-07       Impact factor: 5.738

Review 5.  Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy.

Authors:  Marzia Del Re; Stefania Crucitta; Giulia Gianfilippo; Antonio Passaro; Iacopo Petrini; Giuliana Restante; Angela Michelucci; Stefano Fogli; Filippo de Marinis; Camillo Porta; Antonio Chella; Romano Danesi
Journal:  Int J Mol Sci       Date:  2019-08-14       Impact factor: 5.923

Review 6.  Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers-Applications and Limitations.

Authors:  Shuta Ohara; Kenichi Suda; Tetsuya Mitsudomi
Journal:  Cells       Date:  2021-02-09       Impact factor: 6.600

Review 7.  Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments.

Authors:  Marc G Denis; Jaafar Bennouna
Journal:  Cancer Manag Res       Date:  2020-12-08       Impact factor: 3.989

8.  Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors.

Authors:  Lei Zhang; John Coffin; Kim Formenti; Quincy Chu; Iyare Izevbaye
Journal:  BMJ Open Respir Res       Date:  2022-01

9.  Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.

Authors:  Silvia La Monica; Roberta Minari; Daniele Cretella; Mara Bonelli; Claudia Fumarola; Andrea Cavazzoni; Maricla Galetti; Graziana Digiacomo; Federica Riccardi; Pier Giorgio Petronini; Marcello Tiseo; Roberta Alfieri
Journal:  Target Oncol       Date:  2019-10       Impact factor: 4.493

Review 10.  Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.

Authors:  Alessandro Leonetti; Sugandhi Sharma; Roberta Minari; Paola Perego; Elisa Giovannetti; Marcello Tiseo
Journal:  Br J Cancer       Date:  2019-09-30       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.